Summary List PlacementJust months after breaking the record for largest funding round in the psychedelics field, Atai Life Sciences has raised another $157 million to continue to develop treatments for mental illnesses like depression, addiction, and anxiety. On Wednesday, Atai announced that it had closed its Series D financing round, which was led by existing investors Apeiron Investment Group, Christian Angermayer, Thiel Capital and new investor Woodline Partners LP, an investment firm that focuses on equity strategy within healthcare and technology.